Tirzepatide doses range from 2.5 mg to 15 mg weekly, whereas semaglutide doses typically max out at 2 mg weekly for diabetes and up to 2.4 mg for weight management
Behavioural support programmes such as those offered through NHS weight management services can provide structure, accountability, and evidence-based strategies
An oral semaglutide formulation (Rybelsus) has been approved for treating type 2 diabetes patients and is now in late-stage clinical development for the treatment of obesity
Nature 445 , 881885 (2007) Stingo, F.C., Chen, Y.A., Tadesse, M.G., Vannucci, M.: Incorporating biological information into linear models: a Bayesian approach to the selection of pathways and genes
A., Mignion, L., Desmet, C., Gourgue, F., Jonas, J